



Innovex International Q3 2025 Earnings Presentation

Disclaimer

Important Information and Disclaimers

This disclaimer applies to this document and the verbal or written comments of any person presenting it. This document, taken together with any such verbal or written comments, is referred to herein as the "Presentation."

Historical financial results presented in this Presentation as averages or annualized forms are not necessarily indicative of results that may be expected for any future period.

Cautionary Statement Regarding Forward-Looking Statements

This Presentation contains forward-looking statements about Innovex International, Inc. ("Innovex," "INVX," the "Company," "we" or "us") and its industry that involve substantial risks and uncertainties. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of Innovex's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements can be identified by the use of forward-looking terminology, including "may," "believe," "expect," "intend," "anticipate," "plan," "should," "estimate," "continue," "potential," "will," "hope" or other similar words and include the Company's expectation of future performance contained herein. These statements discuss future expectations, contain projections of results of operations or of financial condition, or state other "forward-looking" information, including without limitation statements regarding the expected benefits of the sale of the Eldridge facility. You are cautioned not to place undue reliance on any forward-looking statements, which can be affected by assumptions used or by risks or uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Innovex that any of its plans will be achieved. When considering these forward-looking statements, you should keep in mind the risks related to the Company's merger and acquisition activities, including the ultimate outcome and results of integrating operations, the effects of the Company's merger and acquisition activities (including the Company's future financial condition, results of operations, strategy and plans), potential adverse reactions or changes to business relationships resulting from the completion of mergers and acquisitions, expected benefits from mergers and acquisition and the ability of the Company to realize those benefits, the significant costs required to integrate operations, whether merger or acquisition-related litigation will occur and, if so, the results of any litigation, settlements and investigations, operating hazards, natural disasters, weather-related delays, casualty losses and other matters beyond our control; acts of terrorism, war or political or civil unrest in the United States or elsewhere; loss or corruption of our information or a cyberattack on our computer systems; the risks related to economic conditions and other factors noted in the Company's Annual Report on Form 10-K, any Quarterly Reports on Form 10-Q and the other documents that the Company files with the Securities and Exchange Commission. The risk factors and other factors noted therein could cause actual results to differ materially from those contained in any forward-looking statement. Innovex disclaims any duty to update and does not intend to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this press release, except as may be required by law.



Disclaimer (Cont'd)

Industry Information

We obtained the industry, market and competitive position data used throughout this Presentation from our own internal estimates and research, as well as from independent industry publications, government publications and other published independent sources. Internal estimates are derived from publicly available information released by industry analysts and third-party sources, our internal research and our industry experience and are based on assumptions made by us based on such data and our knowledge of the industry and market, which we believe to be reasonable. In addition, while we believe the industry, market and competitive position data included in this Presentation is reliable and based on reasonable assumptions, we have not independently verified the accuracy or completeness of any third-party information. Some data is also based on our good faith estimates. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors. These and other factors could cause results to differ materially from those expressed in these publications. Forecasts and other forward-looking statements obtained from these sources are subject to the same qualifications and uncertainties as the other forward-looking statements in this Presentation. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information contained herein and no reliance should be placed on it. None of Innovex, the underwriters or any of their respective affiliates, advisers, connected persons or any other person accept any liability for any loss howsoever arising (in negligence or otherwise), directly or indirectly, from this Presentation or its contents or otherwise arising in connection with this Presentation. This shall not, however, restrict or exclude or limit any duty or liability to a person under any applicable law or regulation of any jurisdiction that may not lawfully be disclaimed.

The information contained in this Presentation is provided as at the date of this Presentation and is subject to change without notice.

Financial Information: Non-GAAP Financial Measures

This Presentation contains both financial measures prepared and presented in accordance with generally accepted accounting principles ("GAAP") and non-GAAP financial measures, which are measurements of financial performance that are not prepared and presented in accordance with GAAP. Accordingly, these measures should not be considered as a substitute for data prepared and presented in accordance with GAAP. These non-GAAP financial measures, including Adjusted EBITDA, Adjusted EBITDA Margin, Return on Capital Employed ("ROCE") and Free Cash Flow, are or have been used by Innovex's management when evaluating results of operations and as otherwise described below. Non-GAAP financial measures should not be construed as being more important than comparable GAAP measures. Innovex's management believes these non-GAAP financial measures provide users of our financial statements with additional and useful comparisons of current results of operations with past and future periods. Although we use or have used these non-GAAP financial measures to assess the performance of our business and for the other purposes, the use of these non-GAAP financial measures as an analytical tool has limitations, and you should not consider them in isolation, or as a substitute for analysis of our results of operations as reported in accordance with GAAP. In addition, because not all companies use identical calculations, the non-GAAP financial measures included in this Presentation may not be comparable to similarly titled measures disclosed by other companies, including our peers or other companies in our industry. Please see "Appendix: GAAP Reconciliations" within the Presentation for reconciliations of the non-GAAP financial measures included in the Presentation to our most directly comparable financial measures calculated and presented in accordance with GAAP.

Management has provided outlook regarding Adjusted EBITDA, which is a non-GAAP financial measure and excludes certain charges. A reconciliation of this non-GAAP financial measure to the corresponding GAAP financial measure has not been provided because guidance for the various reconciling items is not provided. The Company is unable to provide guidance for these reconciling items because they cannot determine their probable significance, as certain items are outside of the Company's control and cannot be reasonably predicted since these items could vary significantly from period to period. Accordingly, reconciliations to the corresponding GAAP financial measures are not available without unreasonable effort.

Use of Website

Investors should note that Innovex announces material financial information in SEC filings, press releases and public conference calls. Innovex may use the Investors section of its website (www.innovex-inc.com) to communicate with investors. It is possible that the financial and other information posted there could be deemed to be material information. Information on Innovex's website is not part of this Presentation.

Curated Portfolio of Complementary, Mission Critical Products

Big impact/small ticket product proposition

High FCF¹ Conversion

50-60% of Adjusted EBITDA² is converted into free cash flow under normal business conditions

Resilient Gross Margins

32-34% LTM

Diversified Presence Across the Most Attractive Global Markets


Shorter cycle **NAM Land** and longer cycle **International & Offshore**

Capital Light, High Return (ROCE³) Model

Historically only 2-3% of revenue is reinvested into capex

Strong balance sheet

Net cash position provides ability to remain opportunistic across the cycle



(1) Free Cash Flow is a non-GAAP measure. We define Free Cash Flow as cash provided by operations less capital expenditures.
 (2) Adjusted EBITDA is a non-GAAP measure. We define Adjusted EBITDA as net income before interest expense, income tax expense, depreciation and amortization, and other expense, net, further adjusted to exclude certain items which we believe are not reflective of our ongoing performance or which are non-cash in nature.
 (3) Return on Capital Employed ("ROCE") is a non-GAAP measure. We define ROCE as Income from Operations, before acquisition costs and after tax (resulting in Adjusted Income from Operations, after tax) divided by average capital employed. Capital employed is defined as the combined values of debt and stockholders' equity.

Innovex Today


Track record of successful, disciplined growth since inception

Proven and Successful Business Model

- **Disciplined Revenue Growth:** 27% revenue CAGR since inception¹ under a low leverage framework
- **Returns Focused:** ROCE² outperformed S&P 500 from 2018 thru 2024
- **Attractive Margin and Low Capex Profile:** High margins with negligible sustaining capital requirements
- **Through Cycle Playbook:** Strategy performs well across all market environments

Runway for Sustained Growth

- **Innovation:** New product development drives revenue growth and expands our addressable market
- **Geographic & Market Share Expansion:** Continued organic market share growth within North America, with sizeable opportunities in International & Offshore markets
- **Disciplined Curation:** Qualitative and Quantitative framework applied to all investments and divestments
- **Strong Market Tailwinds:** Growing domestic service intensity coupled with sustained International & Offshore investment



Source: FactSet, Public Disclosure. S&P 500 represents the median metric for current constituents. (1) Since inception of Legacy Innovex (2) ROCE is a non-GAAP measure and defined as operating income plus acquisition costs less income tax expense divided by average book equity, book debt, and noncontrolling interest. See appendix for reconciliation to Innovex's most comparable GAAP measure.

Innovex's *No Barriers* Culture

No Barriers between our customers and our employees

No Barriers to our ongoing success



Q3 2025 Performance & Q4 2025 Outlook


Q3 2025 Commentary

- Revenue of \$240 million, up 7% sequentially
- Net income of \$39 million
- Adjusted EBITDA⁽²⁾ of \$44 million and Adjusted EBITDA Margin⁽²⁾ of 18%
- Net cash from operations of \$48 million
- Free Cash Flow⁽³⁾ of \$37 million


Q4 2025 Guidance

- **Revenue:** \$235 – 245 million
- **Adjusted EBITDA:** \$42 – 47 million
- **Market Assumption:** Flat to down activity levels, with product mix on subsea deliveries and facility consolidation costs continuing to weigh on margins

Financial Performance⁽¹⁾⁽²⁾



Quarterly Free Cash Flow⁽³⁾



(1) Financial data for Q4 2023 through Q2 2024 shown on an "as reported" basis for Legacy Innovex.

(2) Adjusted EBITDA and Adjusted EBITDA Margin are non-GAAP measures. We define Adjusted EBITDA as net income before interest expense, income tax expense, depreciation and amortization, and other expense, net, further adjusted to exclude certain items which we believe are not reflective of our ongoing performance or which are non-cash in nature. We define Adjusted EBITDA Margin as Adjusted EBITDA divided by revenue. See appendix for reconciliation to Innovex's most comparable GAAP measures.

(3) Free Cash Flow is a non-GAAP measure. We define Free Cash Flow as cash provided by operations less capital expenditures. See appendix for reconciliation to Innovex's most comparable GAAP measures.

No Barriers Culture Driving Operational Transformation


Innovex's Proven Playbook in Action

Closed on \$90 million sale of Eldridge Facility

- Net proceeds¹ of \$87 million
- 80% Footprint Reduction: from 113 acres to ~23 acres
- Significantly enhances an already net cash position

Transforming operating model to drive higher margins and enhance the customer experience

- Optimize direct to indirect manufacturing personnel ratios
- Consolidate global manufacturing and operations facilities
- Smaller, more flexible supply chain model will improve on-time delivery
- Smaller footprint will improve collaboration through proximity, facilitating No Barriers Culture.



Q3: Disciplined M&A framework and Cycle Playbook in Action

Early revenue synergies enhancing deal economics

Organic Growth

- **Gaining Share in US Land:** US land portfolio continues to outpace the underlying market
- **Gaining Share in Subsea:** Partnership with OneSubsea grows addressable market and market share
- **International Expansion:** Legacy Citadel products undergoing trials in key international markets


Improving the Customer Experience

- **On-Time Delivery:** Subsea OTD continues to improve, now up to 76% in Q3 2025 from <50% in Q3 2024
- **Value Add Technology:** TrenchFoot™ wet shoe solution grew share by increasing reservoir access and reducing cycle times. Adoption rate of this technology continues to increase


Cash Generative and Capital Disciplined

- **\$90 Million Sale of Eldridge:** Net proceeds¹ of \$87 million
- **High FCF² Yield:** 84% of Adjusted EBITDA³ was converted into FCF in Q3
- **Opportunistic:** Large cash balance and \$100mm buyback authorization, with approximately \$90.7mm remaining

Clear Path to Margin Enhancement via Cost Synergies



Significant Adjusted EBITDA Margin Opportunity⁴



(1) Net proceeds value is defined as final sale price less leaseback and real estate tax prorrations, broker fees, and title/escrow fees.

(2) Free Cash Flow is a non-GAAP measure. We define Free Cash Flow as cash provided by operations less capital expenditures.

(3) Adjusted EBITDA is a non-GAAP measure. We define Adjusted EBITDA as net income before interest expense, income tax expense, depreciation and amortization, and other expense, net, further adjusted to exclude certain items which we believe are not reflective of our ongoing performance or which are non-cash in nature.

(4) Adj. EBITDA Margin is a non-GAAP measure. See appendix for reconciliation to Legacy Dril-Quip's and Legacy Innovex's most comparable GAAP measures. Legacy Dril-Quip's Adj. EBITDA margin was (14%) in Q1 2021 and (60%) in Q4 2021.

We use the cycle to drive growth

Current market conditions present opportunity

Up-Cycle

- Prioritize execution to drive market share capture
- Expand margins through strategic price increases
- Invest in inventory to support customer needs
- Maintain focused acquisition approach
- Divest underperforming or noncore product families

Mid-Cycle

- Maintain balance sheet strength
- Optimize margins and focus on process improvement
- Maintain focused acquisition approach
- Continually prune non-core product lines from portfolio

Down-Cycle

- Invest while competitors struggle
- Unwind working capital to bolster liquidity
- Evaluate transformative opportunities
- Continually prune non-core product lines from portfolio

Cycles are a *feature*, not a bug of the business model.

We maintain a fortress balance sheet to allow us to profit from volatility.



We Generate Real Cash and Actual Returns by Leveraging our Platform

We curate our portfolio based on underlying economic potential, not pitchbook logic

The Innovex Approach

- ✓ Invest in small ticket, big impact products
- ✓ Drive organic growth through customer focused innovation
- ✓ Apply *No Barriers* approach to achieve exceptional margins and free cash flow, leveraging our industrial platform, and attracting long term investors
- ✓ Actively curate a product portfolio that fully integrates with our existing R&D framework
- ✓ Use disciplined approach to M&A and divestitures, enhancing growth with products that fit our approach, at valuations that drive strong returns
- ✓ Defend the strength of our balance sheet

Typical OFS Playbook

- ✗ Aggregate EBITDA
- ✗ Consolidate via a “roll up” strategy
- ✗ Chase “scale,” regardless of the underlying economic moat, to become a cyclical “play” on a cycle
- ✗ Combine distinct segments and business lines that operate autonomously
- ✗ Pay high M&A multiples with low realized ROCE¹
- ✗ Aggressive use of leverage to justify “accretion”

(1) Return on Capital Employed (“ROCE”) is a non-GAAP measure. We define ROCE as Income from Operations, before acquisition costs and after tax (resulting in Adjusted Income from Operations, after tax) divided by average capital employed. Capital employed is defined as the combined values of debt and stockholders’ equity.



INNOVEX



Appendix: GAAP Reconciliations

Innovex International Reconciliation to Non-GAAP Metrics

Quarterly Net Income to Adjusted EBITDA

(\$ in millions)	Q3'24 ¹	Q4'24	Q1'25	Q2'25	Q3'25
Net Income	\$83	\$32	\$15	\$15	\$39
(+) Net Interest Expense	1	0	1	1	1
(+) Income Tax Provision	(3)	(4)	7	7	19
(+) Depreciation and Amortization Expense	8	12	15	15	15
(-) Other Expense / (Income)	(0)	1	(0)	(0)	(0)
(+) EBITDA Contribution from Minority Investment	1	1	0	0	0
(+) Non-Recurring Expenses	(61)	9	6	9	(30)
Adjusted EBITDA	\$27	\$49	\$46	\$47	\$44
<i>Net Income Margin %</i>	54%	13%	6%	7%	16%
<i>Adjusted EBITDA Margin %</i>	18%	20%	19%	21%	18%

(1) Reflects Legacy Innovex's results through September 6, 2024 and the combined results of Innovex and Dril-Quip for the balance of the quarter.

Innovex International Reconciliation to Non-GAAP Metrics

Quarterly Free Cash Flow

(\$ in millions)	Q3'24 ¹	Q4'24	Q1'25	Q2'25	Q3'25
Cash Flow from Operating Activities	\$22	\$36	\$31	\$59	\$48
Capital Expenditures	(2)	(8)	(7)	(7)	(12)
Free Cash Flow	\$20	\$29	\$24	\$52	\$37

(1) Reflects Legacy Innovex's results through September 6, 2024 and the combined results of Innovex and Dril-Quip for the balance of the quarter.



Legacy Standalone Innovex Reconciliation to Non-GAAP Metrics

Annual Adjusted EBITDA and Adjusted EBITDA Margin

(\$ in millions)	2023	2022	2021	2020 ²	2019 ²	2018 ²
Revenue	\$556	\$467	\$295	\$189	\$325	\$277
Net Income	74	63	10	(5)	32	35
Interest Expense, Net	6	4	2	2	4	4
Income Tax Expense	20	10	4	2	9	(4)
Depreciation & Amortization	23	18	18	24	22	19
EBITDA	123	95	34	23	68	54
Other Expense, Net ¹	(2)	(0)	(2)	(1)	(2)	0
Other Adjustments ³	12	7	9	7	5	4
Adjusted EBITDA	\$132	\$102	\$41	\$29	\$71	\$59
<i>Net Income Margin %</i>	<i>13%</i>	<i>14%</i>	<i>3%</i>	<i>(3%)</i>	<i>10%</i>	<i>13%</i>
<i>Adjusted EBITDA Margin %</i>	<i>24%</i>	<i>22%</i>	<i>14%</i>	<i>15%</i>	<i>22%</i>	<i>21%</i>

(1) Represents IPO preparation costs, our percentage ownership interest in the EBITDA of our minority investment, transaction and acquisition integration expenses, and certain other non-recurring or non-cash items.

(2) 2020, 2019 and 2018 financial information has not been audited in accordance with PCAOB standards.

(3) Primarily represents foreign currency exchange gain/loss, gain/loss related to disposal of assets, elimination of equity income/loss from minority investment, and other non-operating items.